Pragmatic Versus Explanatory Trials, and Why You Need Both to Read the Evidence

An explanatory trial asks whether a treatment can work when everything is arranged in its favor: ideal patients, expert sites, careful adherence, close monitoring. A pragmatic trial asks whether the same treatment does work in ordinary care, among the patients and clinicians who will actually use it, with all the mess that implies. Both are randomized. Both can be excellent. The mistake to avoid is treating a result from one as if it answered the question the other was built for. A clean efficacy signal does not promise everyday benefit, and a flat real-world result does not prove the biology is wrong.

I have stood on both sides of this line. My doctoral research at the Lund University Diabetes Centre is mechanism-first work on the genetics of type 2 diabetes, which lives at the explanatory end. Later, building a clinical decision-support system, I helped run a randomized trial designed to behave like real practice. The two settings reward almost opposite instincts, and knowing which one you are reading changes what a result is allowed to mean.

What is the difference between a pragmatic and an explanatory trial?

Here is the short, quotable version. An explanatory trial measures whether an intervention produces an effect under optimal, tightly controlled conditions; it answers the question of efficacy, can this work. A pragmatic trial measures whether the intervention helps under usual conditions of care; it answers the question of effectiveness, does this work, here, for these people.

The contrast is not a binary. It is a spectrum, and almost every real trial sits in the middle. The useful habit is to ask, for each design choice, which way it leans. Tight criteria, run-in periods that screen out poor adherers, dosing managed by specialists, and visits no clinic could sustain pull toward the explanatory end. Broad eligibility, ordinary clinicians delivering the treatment, outcomes patients can feel, and follow-up through normal records pull toward pragmatic.

Why would anyone want the artificial version?

Because it answers a question you need answered first. If you want to know whether a mechanism does anything at all, you want every source of noise stripped out. The explanatory design gives a true effect its best chance to show itself, so that a null result means it is small or absent rather than buried under variability.

Think of it as testing an engine on a bench before putting it in a car. You control the fuel, the temperature, the load, because you are asking a narrow and honest question: under these conditions, does it turn over. A clean explanatory trial is how a field establishes that a biological idea is real before spending to find out whether it survives the world. Skip this step and you only learn the hard truths later, at greater cost.

The cost is that the trial's patients are not your patients. People who enroll in demanding trials tend to be younger, less burdened by other illnesses, more adherent, and cared for at centers that do this for a living. The effect you measure is the ceiling, not the floor.

What does a pragmatic trial buy you, and what does it cost?

A pragmatic trial trades precision for relevance. By enrolling broadly and delivering the treatment the way a real clinic would, it tells you what to expect when the engine is in the car, on a cold morning, with a driver who forgets to service it. That is the number a health system needs to plan around.

The price is that everything which makes it realistic also makes it noisier. Patients miss doses, some drift to the other group's treatment, and clinicians vary in how they deliver the protocol. All of this dilutes the measured effect, so a pragmatic trial usually reports a smaller benefit than its explanatory cousin on the same treatment. A modest pragmatic result is often the efficacy effect seen through the friction of real life, not evidence that the treatment is weak.

This is also where intention-to-treat analysis earns its keep. Analyzing people in the group they were assigned to, whether or not they took the treatment, sounds like it punishes a good drug. In a pragmatic trial it is exactly right, because non-adherence is part of what you are measuring. If a third of patients will not stay on a treatment in practice, a health system needs the benefit including that third, not the benefit among the disciplined minority who stuck with it.

How can the same treatment look strong in one trial and weak in another?

Most often, nothing has gone wrong: the two trials asked different questions and got two honest answers. A common trap is to read the explanatory result as a promise, then feel cheated when practice underdelivers. The efficacy figure was never a forecast of average benefit. It measured what is possible under near-ideal conditions, a narrower claim. The reverse trap is just as costly: dismissing a sound mechanism because a pragmatic trial showed a muted effect, when the muting came from delivery and adherence rather than from biology.

A subtler failure is easy to commit in good faith. A trial can be dressed in pragmatic language, broad eligibility and a real-world setting, while quietly keeping explanatory machinery, an outcome no ordinary clinic measures or monitoring no clinic could fund. The result then generalizes to nowhere: too controlled for real practice, too loose to isolate a mechanism. The fix is honesty about where each design choice sits.

How should a careful reader use the distinction?

Read the methods before the result, and locate the trial on the spectrum first. Who was eligible, and who was quietly excluded by run-in periods or strict criteria? Who delivered the treatment? Was the outcome something patients feel, or a measurement that only exists inside a study? How was non-adherence handled? The answers tell you whether you are looking at a ceiling or an average, and structured tools exist to score this rather than judge it by impression.

When I helped run our decision-support trial, the EASY-1 randomized controlled trial (NCT03258268), we deliberately built it to behave like real practice. It was a multi-clinic study that used the clinicians who would actually use the tool, and measured outcomes and workflow efficiency a clinic cares about, because the claim we had to defend was about ordinary care, not a laboratory ideal.

The two designs are partners, not rivals. Explanatory trials tell you whether an idea is true; pragmatic trials tell you whether the truth is useful where people live. A field that runs only explanatory trials accumulates effects that never reach patients; one that runs only pragmatic trials never learns why something failed. The reader who keeps both questions in mind, can it work and does it work here, finishes far harder to fool. This article is educational and not medical advice; for any decision about your own care, talk it through with your clinician.